In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Factors in nonspecific inflammation with the patients with non-ST-segment elevation acute coronary syndrome with in conjunction multifocal atherosclerosis

Session Poster Session III - Friday 08:30 - 12:30

Speaker Evgeniya Shmidt

Event : ESC Preventive Cardiology (Formerly EuroPrevent) 2015

  • Topic : preventive cardiology
  • Sub-topic : Risk Factors and Prevention
  • Session type : Poster Session

Authors : EA Shmidt (Kemerovo,RU), SA Berns (Kemerovo,RU), OL Barbarash (Kemerovo,RU), ES Ykhno (Kemerovo,RU)

Authors:
EA Shmidt1 , SA Berns1 , OL Barbarash1 , ES Ykhno1 , 1Research Institute for Complex Issues of Cardiov. Dis. - Siberian Branch RAMS Institution Scientific - Kemerovo - Russian Federation ,

Topic(s):
Risk factors: others

Objective:  to define the clinical and prognostic role of cytokines with the non-ST-segment elevation acute coronary syndrome (nonST-ACS) patients along with the multifocal atherosclerosis (?F?).
Materials and methods: 266 patients suffering from ACS (unstable angina (UA) or non-Q-wave myocardial infraction (MI) occurring within 48 hours prior to hospitalization) had coronary angiography, colour duplex scanning of extra cranial arterias and lower extremity arterias performed. 93 patients had the level of interleukine (IL)-1a,  -6, -8, -10, and the tumor necrosis factor-a (TNF-a). «End points» development (UA, non-fatal MI and apoplectic attack, cardiovascular death) during the period of hospitalization and during one year of observation.
Results. Accurate reduction in the concentration of IL-8 with the patients who have 3 vascular systems involvments (coronary arterias (C?), extracranial and peripheral arteries) as compare with the patients without stenosis involvements (?=0.02). The significant increase of the level IL-6 was associated with the age older than 65 (4.28(2.65; 7.84) and 8.22 (4.70; 10.43), consequently, ?=0.01), with smoking (8.89(4.62; 11.69) and 5.88(3.11; 9.45), consequently, ?=0.04), with the left ventricular ejection fraction less than 40% (13.82(9.74; 16.02) and 6.23(3.68; 9.54), ?=0.009). The significant increase of the level TNF-a was observed with the age older than 65 (9.39(6.78; 12.86) and 13.33(8.84;18.75), consequently, ?=0.03), apoplectic attack in past medical history (16.71(11.27;20.21) and 10.84(8.00;16.22), consequently, ?=0.049). Increase of the level IL-1a was associated with the male gender (5.29 (5.74; 6.27) and 3.80(5.00;5.54), ?=0.02). IL-8 demonstrated the tendency to the accurate increase with the patients who have the apoplectic attack in their medical history (7.63 (3.71; 22.11) and 5.20 (2.82; 6.92), ?=0.06). Among all the studied cytokines the accurate influence on the hospital prognosis was made by the level IL-10 solely. When this level rose (>0.5 pg/ml), the composite «end point» developed 3.8 times more often (?=0.02). TNF-a increase solely was relevant for the annual prognosis. The frequency of the composite «end point» development with the patients granting its increased level (>16.83 pg/ml) rose 2.1 times (?=0.04).
Conclusions: 1) IL-8 has a protective effect on the atherosclerosis development; 2) IL-10 defining is important for the hospital prognosis with the patients suffering from ACS, for the annual prognosis TNF-a defining is relevant.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are